Schrodinger (SDGR) stock falls as Citi downgrades the company following its decision to halt a clinical development program for a leukemia candidate. Read more here.

TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel ...

Third Patient Treated with HG-CT-1 CAR-T Therapy and Completion of First Adult Dose Cohort LONDON, UNITED KINGDOM / ACCESS ...

Amir Fathi, MD, leukemia specialist at Massachusetts General Hospital, discusses the importance of advocacy by both patients ...

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Friday said a third patient has been successfully treated under its phase one trial of its CAR-T cell therapy, HG-CT-1, for relapsed or refractory ...

Schrödinger (Nasdaq: SDGR) has halted the clinical development of its oral drug SGR-2921 following the occurrence of two ...

Stillpoint Mission; kickoff for Walk to End Alzheimer’s; Big Waters fundraiser; Sarasota/Manatee MPO meeting; youth grief ...

There's been a major decrease in blood donations, due to many people being away for the summer, which is why non-profit ...

Schrödinger has halted development of its cancer-fighting candidate SGR-2921 after two patients treated with the CDC7 inhibitor died in a Phase I trial.

LAVA Therapeutics ( ($LVTX) ) has issued an announcement. On August 13, 2025, LAVA Therapeutics announced its acquisition by XOMA Royalty ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...

GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2's formal safety review, it has advanced into Cohort 3 and ...